- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04979910
Targeting IL-17A for Treatment-Resistant Depression
An Experimental Therapeutics Study of a Monoclonal Antibody Against Interleukin 17A in Patients With Treatment-Resistant Depression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Esther Lee, BS
- Phone Number: (512) 636-1981
- Email: esther.lee@mssm.edu
Study Contact Backup
- Name: Sara Hameed, BA
- Phone Number: (212) 585-4622
- Email: sara.hameed@mssm.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10025
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Principal Investigator:
- James W Murrough, MD, PhD
-
Contact:
- Mirabel Sleiman, BA
- Phone Number: 212-585-6136
- Email: mirabel.sleiman@mssm.edu
-
Contact:
- Julia Clark
- Phone Number: 212-241-6539
- Email: julia.clark@mssm.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent (and assent when applicable) obtained from subject;
- Ability for subject to comply with the requirements of the study as determined by the PI;
- Men and women, age 18-70 years;
- Participants must meet DSM-5 criteria for Major Depressive Disorder [MDD]) in a current major depressive episode (MDE) as determined by a study psychiatrist and confirmed using the Structured Clinical Interview for DSM-5 Research Version (SCID-5-RV);
- Participants have had ≥ 2 adequate trials of antidepressants/augmentation strategies during current episode. (Refer to ATRQ Guidelines for Completion for guidelines on dose/duration required for a trial to be considered adequate.);
- Patients must be on a stable dose of antidepressant medication for >4 weeks prior to randomization;
- CRP level ≥ 1mg/L at screening;
- Quick Inventory of Depressive Symptoms - Clinician Administered (QIDS-C) score ≥ 14
- If female of childbearing potential, must agree to use of a medically accepted form of contraception, or else agree to abstinence until 6 months after the last dose of study drug.
- Male patients, if heterosexually active with a partner who is female of childbearing potential, pregnant, or breastfeeding, must agree to barrier contraception for the treatment period and for at least 6 months after the last dose of study drug. Female partners of male participants must use at least one form of highly effective contraception starting at least one cycle prior to male patient study drug initiation until 6 months after the last dose of study drug.
Exclusion Criteria:
- A primary psychiatric diagnosis other than MDD as defined by DSM-5; [comorbid anxiety disorders (including agoraphobia, generalized anxiety disorder, social anxiety disorder and panic disorder) and posttraumatic stress disorder (PTSD) are allowed];
- Has a history of schizophrenia or other psychotic disorder, major depressive disorder with psychotic features, or bipolar I or II disorder;
- Diagnosis of a major neurocognitive disorder;
- Meets criteria for a moderate or severe substance use disorder within the past 6 months, with the exception of nicotine use disorder;
- The patient is pregnant or breastfeeding;
- Any contraindication to MRI or gadolinium including claustrophobia, any trauma or surgery which may have left magnetic material in the body, magnetic implants or pacemakers, inability to lie still for 1 hour or more, any known allergy to gadolinium;
- Positive urine toxicology screen for illicit drugs at the time of screening;
- Serious and imminent risk of self-harm or violence as determined by the PI;
- History of suicide attempt in the past 2 years or screening CSSRS Ideation Score >2 in the past month;
- Clinically significant abnormalities of laboratory tests or physical examination;
- Any unstable medical illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease); endocrinologic, neurologic (including history of severe head injury), immunologic, or hematologic disease;
- Presence of TB as assessed by Quantiferon Gold test at screening;
- Concomitant treatments with other biologics or other immune-suppressant agents; PRN use of NSAIDs is permissible;
- Female participants who are pregnant, breastfeeding, or may become pregnant, or unwilling to practice birth control during participation in the study or the 6 months following;
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ixekizumab
Ixekizumab 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2 and 4 via subcutaneous route.
|
a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
|
Placebo Comparator: Placebo
Matching saline placebo at Week 0 (two injections), followed by one injection at Weeks 2 and 4 via subcutaneous route.
|
matching placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Montgomery-Åsberg Depression Rating Scale Score
Time Frame: Baseline and 6 weeks
|
The Montgomery-Åsberg Depression Rating Scale (MADARS) is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms.
Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item.
These individual item scores are added together to form a total score, which can range between 0 and 60 points.
The MADRS provides a measure of the overall level of depression.
Higher score indicates poorer health outcome.
|
Baseline and 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score
Time Frame: Baseline and 6 weeks
|
The Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) is a 16-item self-rated instrument designed to assess the severity of depressive symptoms.
The 16 items cover the nine symptom domains of major depression and are rated on a scale of 0-3.
Total score ranges from 0 to 27, with ranges of 0-5 (normal), 6-10 (mild), 11-15 (moderate), 16-20 (moderate to severe), and 21+ (severe).
Higher score indicates poorer health outcome.
|
Baseline and 6 weeks
|
Change in Snaith-Hamilton Pleasure Scale (SHAPS)
Time Frame: Up to Week 6
|
The Snaith-Hamilton Pleasure Scale (SHAPS) is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia.
Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity.
A total score can be derived by summing the responses to each item.
Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4."
Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
|
Up to Week 6
|
Change in Temporal Experience of Pleasure Scale
Time Frame: Baseline and 6 weeks
|
The Temporal Experience of Pleasure Scale (TEPS) is an 18-item self-report measurement of anhedonia which consists of a series of statements that must be rated according to how accurate they are for the individual.
The scale produces a sub-score that differentiates the role of anticipatory pleasure ('wanting') and is derived of 10 items.
Subscales scores from 9-54.
Total scores range is 16-108.
Lower scores indicate greater levels of anhedonia.
|
Baseline and 6 weeks
|
Change in Clinical Global Impression Scale
Time Frame: Baseline and 6 weeks
|
This is a widely administered clinician rated scale that assesses the subject overall illness severity and the degree of improvement from the initial assessment. Illness severity is rated on a 1-7 scale where 1 corresponds to "Normal, Not at All Ill", 2 is "Borderline Mentally Ill", the anchor for 3 is "Mildly Ill", the anchor for 4 is "Moderately Ill", 5 is "Markedly Ill", 6 is "Severely Ill", and 7 is "Among the Most Extremely Ill Patients". Illness improvement is rated on a 1-7 scale where 1 corresponds to "Very Much Improved", 2 is "Much Improved", the anchor for 3 is "Minimally Improved", the anchor for 4 is "No Change", 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse". |
Baseline and 6 weeks
|
Change in The Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: Baseline and 6 weeks
|
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a comprehensive, semi-structured interview that uniquely measures the full spectrum of suicidality including passive and active suicidal ideation, suicidal intent as well as suicidal behaviors.
Full range from 0 to 9, with higher score indicating higher suicidal ideation severity.
|
Baseline and 6 weeks
|
Change in The Hamilton Anxiety Rating Scale (HAM-A)
Time Frame: Baseline and 6 weeks
|
The Hamilton Anxiety Rating Scale (HAM-A) is a scale of assessments of anxiety states.
The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety).
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.
Higher score indicates poorer health outcomes.
|
Baseline and 6 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: James W Murrough, MD, PhD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 20-1909
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States